What pharmacologic treatments are recommended for Avoidant/Restrictive Food Intake Disorder (ARFID)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No FDA-Approved Medications for ARFID; Psychotherapy is First-Line Treatment

There are currently no pharmacologic treatments specifically recommended or FDA-approved for Avoidant/Restrictive Food Intake Disorder (ARFID). The 2023 American Psychiatric Association practice guidelines for eating disorders do not include any medication recommendations for ARFID, focusing instead on psychotherapy as the primary treatment modality 1.

Primary Treatment Approach

The evidence strongly supports psychotherapy as the cornerstone of ARFID treatment, not medication:

  • Family-based treatment (FBT-ARFID) is superior to individual therapy for promoting weight gain in underweight children ages 6-12, particularly those with more severe ARFID symptoms 2
  • Cognitive-behavioral therapy (CBT) adaptations show promise for ARFID treatment 3
  • Treatment should involve a multidisciplinary team incorporating medical, psychiatric, psychological, and nutritional expertise 1

Off-Label Medication Use: Limited Evidence

While no medications are guideline-recommended, emerging research suggests potential off-label options when psychotherapy alone is insufficient:

Atypical Antipsychotics (Primarily Risperidone)

  • A 2025 retrospective study of 21 children showed significant weight gain (9.66 kg), height gain (10.23 cm), and BMI increase (2.55 kg/m²) over 18 months with atypical antipsychotics 4
  • Adverse effects were minimal with no discontinuations due to side effects 4
  • Critical caveat: This is retrospective, uncontrolled data from a single center—not high-quality evidence

Mirtazapine

  • Case reports describe successful use in combination with family-based therapy and partial hospitalization 5
  • No controlled trial data available

Clinical Algorithm

When considering pharmacotherapy for ARFID:

  1. First: Implement evidence-based psychotherapy (FBT-ARFID for children with involved caregivers, CBT adaptations for others) 2, 3

  2. If inadequate response after 6+ months of psychotherapy and significant medical/nutritional compromise persists:

    • Consider off-label atypical antipsychotics (risperidone most studied) for weight/height restoration 4
    • Consider mirtazapine as alternative based on case report data 5
  3. Monitor closely: Weight, height, BMI, metabolic parameters, and medication side effects

  4. Treat co-occurring conditions: If anxiety, depression, or other psychiatric disorders are present and contributing to food avoidance, treat these with appropriate evidence-based medications for those specific conditions

Important Caveats

  • The medication evidence for ARFID is extremely limited—mostly retrospective case series and case reports, not randomized controlled trials
  • Unlike bulimia nervosa (where fluoxetine is recommended) or binge-eating disorder (where lisdexamfetamine or antidepressants are suggested), ARFID has no comparable medication evidence base 1
  • Any medication use should be considered adjunctive to psychotherapy, never as monotherapy
  • The mechanism by which atypical antipsychotics might help ARFID (appetite stimulation, reduced anxiety around eating) differs fundamentally from their use in other eating disorders 4

In real-world practice, prioritize intensive psychotherapy and nutritional rehabilitation before considering off-label medications, and only use medications when medical stability is at risk despite adequate psychotherapeutic intervention.

Related Questions

What are the recommended treatment strategies for avoidant/restrictive food intake disorder (ARFID)?
Are dietitians trained in Avoidant/Restrictive Food Intake Disorder (ARFID) or other eating disorders?
In a 5‑year‑old diagnosed with avoidant/restrictive food intake disorder (ARFID), is there evidence that the parent caused the disorder because the child eats foods during feeding therapy but refuses them at home, and what evidence‑based factors (temperament, sensory sensitivity, anxiety, neurodevelopmental conditions, gastrointestinal experiences, learning/conditioning, and feeding environment) explain this discrepancy and guide appropriate parental involvement in treatment?
Should I hide vegetables in the safe foods of my child with avoidant/restrictive food intake disorder (ARFID)?
What is the recommended evaluation and management for a child with avoidant‑restrictive food intake disorder (ARFID)?
What are the recommended dosing protocols for epoetin alfa and darbepoetin alfa in anemia due to chronic kidney disease or chemotherapy, including monitoring and dose adjustments?
What is the maximum daily dose of Lasix (furosemide)?
How should I treat flu symptoms that are worsening my gastro‑oesophageal reflux disease (GERD)?
What are the steps for placing a central venous catheter?
How should nonspecific ST changes, sinus tachycardia, and an abnormal QRS‑T angle be evaluated and managed in a pregnant patient?
What is the appropriate evaluation and management for a patient with a serum albumin of 1.9 g/dL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.